2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| ATAI Life Sciences N.V. | 10% Owner | 6,905,774 | Sep 27, 2024 |
| ATAI Life Sciences AG | 10% Owner | 6,905,774 | Sep 27, 2024 |
| Malievskaia Ekaterina | 10% Owner | 3,155,122 | Oct 25, 2024 |
| Goldsmith George Jay | 10% Owner | 3,152,848 | Oct 25, 2024 |
| Nath Kabir | CEO | 221,302 | Aug 4, 2025 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Mar 3, 2026 | Loxam Teri | CFO | Sell | 46.3 | -4,467 | -5.37% | ✗ | $31.4K |
| Feb 2, 2026 | Feb 3, 2026 | Nath Kabir | CEO | Sell | 42.5 | -16,181 | -7.31% | ✗ | $107K |
| Oct 29, 2025 | Oct 31, 2025 | JONAS JEFFREY M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 31, 2025 | JONAS JEFFREY M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 1, 2025 | Aug 4, 2025 | Nath Kabir | CEO | Sell | 46.3 | -6,366 | -2.80% | ✗ | $27.6K |
| Jul 29, 2025 | Jul 30, 2025 | Gover Justin D. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 30, 2025 | Gover Justin D. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jun 12, 2025 | Jun 13, 2025 | SANTINI GINO | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Riley Wayne Joseph | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Norton David Y | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | McQuade Robert | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | McGoldrick Linda | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Lonngren Thomas | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Karydas Daphne | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 13, 2025 | Jenkins Annalisa | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 11, 2025 | Mar 13, 2025 | Goodwin Guy | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 11, 2025 | Mar 13, 2025 | Loxam Teri | CFO | Neutral | 90.0 | +25,000 | 42.92% | ✗ | - |
| Mar 11, 2025 | Mar 13, 2025 | Nath Kabir | CEO | Neutral | 90.0 | +92,000 | 67.81% | ✗ | - |
| Mar 3, 2025 | Mar 4, 2025 | Loxam Teri | CFO | Sell | 46.3 | -4,468 | -7.12% | ✗ | $16.4K |
| Feb 3, 2025 | Feb 5, 2025 | Nath Kabir | CEO | Sell | 42.5 | -15,516 | -10.26% | ✗ | $66.9K |
| Oct 24, 2024 | Oct 25, 2024 | Malievskaia Ekaterina | 10% Owner | Neutral | 27.5 | -1,553,130 | -19.76% | ✗ | - |
| Oct 24, 2024 | Oct 25, 2024 | Goldsmith George Jay | 10% Owner | Neutral | 27.5 | -1,553,130 | -19.76% | ✗ | - |
| Sep 26, 2024 | Sep 27, 2024 | ATAI Life Sciences N.V. | 10% Owner | Sell | 15.0 | -2,660,000 | -27.81% | ✗ | $16.1M |
| Sep 3, 2024 | Sep 4, 2024 | SANTINI GINO | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 4, 2024 | SANTINI GINO | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 1, 2024 | Aug 5, 2024 | Jenkins Annalisa | Director | Sell | 50.0 | -161 | -0.82% | ✗ | $1.1K |
| Aug 1, 2024 | Aug 5, 2024 | Nath Kabir | CEO | Sell | 46.3 | -7,064 | -4.46% | ✗ | $48.6K |
| May 20, 2024 | May 22, 2024 | Malievskaia Ekaterina | 10% Owner | Sell | 48.8 | -31,207 | -0.40% | ✓ | $246.6K |
| May 20, 2024 | May 22, 2024 | Goldsmith George Jay | 10% Owner | Sell | 48.8 | -31,207 | -0.40% | ✓ | $246.6K |
| May 9, 2024 | May 13, 2024 | Riley Wayne Joseph | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 9, 2024 | May 13, 2024 | Lonngren Thomas | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 9, 2024 | May 13, 2024 | McGoldrick Linda | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 9, 2024 | May 13, 2024 | Jenkins Annalisa | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 9, 2024 | May 13, 2024 | McQuade Robert | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 9, 2024 | May 13, 2024 | Karydas Daphne | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 9, 2024 | May 13, 2024 | Norton David Y | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 2, 2024 | May 6, 2024 | Goldsmith George Jay | 10% Owner | Sell | 45.0 | -56,766 | -0.71% | ✓ | $490.4K |
| May 2, 2024 | May 6, 2024 | Malievskaia Ekaterina | 10% Owner | Sell | 45.0 | -56,766 | -0.71% | ✓ | $490.4K |
| May 1, 2024 | May 3, 2024 | Jenkins Annalisa | Director | Sell | 47.5 | -211 | -1.06% | ✗ | $1.8K |
| Apr 16, 2024 | Apr 18, 2024 | Goldsmith George Jay | 10% Owner | Sell | 45.0 | -69,461 | -0.87% | ✓ | $598K |
| Apr 16, 2024 | Apr 18, 2024 | Malievskaia Ekaterina | 10% Owner | Sell | 45.0 | -69,461 | -0.87% | ✓ | $598K |
| Apr 1, 2024 | Apr 2, 2024 | Goldsmith George Jay | 10% Owner | Sell | 45.0 | -51,500 | -0.64% | ✓ | $461.3K |
| Apr 1, 2024 | Apr 2, 2024 | Malievskaia Ekaterina | 10% Owner | Sell | 45.0 | -51,500 | -0.64% | ✓ | $461.3K |
| Mar 28, 2024 | Apr 1, 2024 | Malievskaia Ekaterina | 10% Owner | Sell | 45.0 | -51,500 | -0.63% | ✓ | $445.6K |
| Mar 28, 2024 | Apr 1, 2024 | Goldsmith George Jay | 10% Owner | Sell | 45.0 | -51,500 | -0.63% | ✓ | $445.6K |
| Mar 12, 2024 | Mar 14, 2024 | Goldsmith George Jay | Director | Sell | 45.0 | -65,886 | -0.80% | ✓ | $704.8K |
| Mar 12, 2024 | Mar 14, 2024 | Malievskaia Ekaterina | Director | Sell | 45.0 | -65,886 | -0.80% | ✓ | $704.8K |
| Mar 1, 2024 | Mar 5, 2024 | Loxam Teri | CFO | Neutral | 90.0 | +62,718 | 100.00% | ✗ | - |
| Mar 5, 2024 | Loxam Teri | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 23, 2024 | Feb 27, 2024 | Malievskaia Ekaterina | Director | Sell | 45.0 | -59,255 | -0.72% | ✓ | $609.9K |
| Feb 23, 2024 | Feb 27, 2024 | Goldsmith George Jay | Director | Sell | 45.0 | -59,255 | -0.72% | ✓ | $609.9K |
| Feb 6, 2024 | Feb 8, 2024 | Malievskaia Ekaterina | Director | Sell | 42.5 | -85,293 | -1.02% | ✓ | $902.1K |
| Feb 6, 2024 | Feb 8, 2024 | Goldsmith George Jay | Director | Sell | 42.5 | -85,293 | -1.02% | ✓ | $902.1K |
| Feb 1, 2024 | Feb 5, 2024 | OWENS MATTHEW A | General Counsel & CLO | Sell | 91.3 | +21,833 | 101.52% | ✗ | $35.3K |
| Feb 1, 2024 | Feb 5, 2024 | Nath Kabir | CEO | Sell | 91.3 | +88,842 | 128.00% | ✗ | $34.4K |
| Feb 1, 2024 | Feb 5, 2024 | Goodwin Guy | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2024 | Feb 5, 2024 | Hughes Mary-Rose | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 1, 2024 | Feb 5, 2024 | Jenkins Annalisa | Director | Sell | 50.0 | -175 | -0.87% | ✗ | $2K |
| Feb 1, 2024 | Feb 5, 2024 | Goldsmith George Jay | Director | Sell | 47.5 | -10,181 | -0.12% | ✗ | $114.7K |
| Feb 1, 2024 | Feb 5, 2024 | Malievskaia Ekaterina | Director | Sell | 47.5 | -10,181 | -0.12% | ✗ | $114.7K |
| Jan 19, 2024 | Jan 23, 2024 | Goldsmith George Jay | Director | Sell | 42.5 | -91,911 | -1.09% | ✓ | $753K |
| Jan 19, 2024 | Jan 23, 2024 | Malievskaia Ekaterina | Director | Sell | 42.5 | -91,911 | -1.09% | ✓ | $753K |
| Jan 2, 2024 | Jan 4, 2024 | Goldsmith George Jay | Director | Sell | 42.5 | -95,016 | -1.11% | ✓ | $843.9K |
| Jan 2, 2024 | Jan 4, 2024 | Malievskaia Ekaterina | Director | Sell | 42.5 | -95,016 | -1.11% | ✓ | $843.9K |
| Dec 13, 2023 | Dec 15, 2023 | Malievskaia Ekaterina | Director | Sell | 51.3 | -8,464 | -0.10% | ✓ | $66.1K |
| Dec 13, 2023 | Dec 15, 2023 | Goldsmith George Jay | Director | Sell | 51.3 | -8,464 | -0.10% | ✓ | $66.1K |
| Nov 1, 2023 | Nov 2, 2023 | Malievskaia Ekaterina | Director | Sell | 51.3 | -2,996 | -0.04% | ✗ | $17.3K |
| Nov 1, 2023 | Nov 2, 2023 | Jenkins Annalisa | Director | Sell | 50.0 | -143 | -0.71% | ✗ | $826.5 |
| Nov 1, 2023 | Nov 2, 2023 | Goldsmith George Jay | Director | Sell | 51.3 | -2,996 | -0.04% | ✗ | $17.3K |
| Oct 27, 2023 | Hughes Mary-Rose | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Sep 18, 2023 | Sep 20, 2023 | Karydas Daphne | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 20, 2023 | Karydas Daphne | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 1, 2023 | Aug 24, 2023 | Nath Kabir | CEO | Sell | 42.5 | -5,794 | -7.70% | ✗ | $51.9K |
| Aug 1, 2023 | Aug 3, 2023 | Nath Kabir | CEO | Sell | 46.3 | -5,000 | -6.65% | ✗ | $44.8K |
| Aug 1, 2023 | Aug 3, 2023 | Goldsmith George Jay | Director | Sell | 51.3 | -2,996 | -0.04% | ✗ | $26.8K |
| Aug 1, 2023 | Aug 3, 2023 | Malievskaia Ekaterina | Director | Sell | 51.3 | -2,996 | -0.04% | ✗ | $26.8K |
| Aug 1, 2023 | Aug 3, 2023 | Jenkins Annalisa | Director | Sell | 50.0 | -161 | -0.79% | ✗ | $1.4K |
| Jun 2, 2023 | Jun 6, 2023 | McGoldrick Linda | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 2, 2023 | Jun 6, 2023 | Riley Wayne Joseph | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 2, 2023 | Jun 6, 2023 | McQuade Robert | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 2, 2023 | Jun 6, 2023 | Goldsmith George Jay | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 2, 2023 | Jun 6, 2023 | Lonngren Thomas | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 2, 2023 | Jun 6, 2023 | Jenkins Annalisa | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 2, 2023 | Jun 6, 2023 | Norton David Y | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 2, 2023 | May 4, 2023 | Jenkins Annalisa | Director | Sell | 52.5 | -25 | -0.12% | ✗ | $199.3 |
| May 2, 2023 | May 4, 2023 | Malievskaia Ekaterina | Chief Innovation Officer | Sell | 51.3 | -2,996 | -0.04% | ✗ | $23.9K |
| May 2, 2023 | May 4, 2023 | Goldsmith George Jay | Director | Sell | 51.3 | -2,996 | -0.04% | ✗ | $23.9K |
| Feb 2, 2023 | Feb 3, 2023 | Goodwin Guy | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 20, 2022 | Feb 3, 2023 | Malievskaia Ekaterina | Chief Innovation Officer | Sell | 47.5 | -5,870 | -0.07% | ✗ | $173.7K |
| Feb 2, 2023 | Feb 3, 2023 | FALVEY MICHAEL | CFO | Neutral | 90.0 | +22,500 | 100.00% | ✗ | - |
| Feb 1, 2023 | Feb 3, 2023 | OWENS MATTHEW A | General Counsel & CLO | Sell | 91.3 | +9,107 | 73.44% | ✗ | $18K |
| Dec 20, 2022 | Feb 3, 2023 | Goldsmith George Jay | Director | Sell | 47.5 | -5,870 | -0.07% | ✗ | $173.7K |
| Feb 2, 2023 | Feb 3, 2023 | Nath Kabir | CEO | Neutral | 90.0 | +25,200 | 50.40% | ✗ | - |
| Aug 1, 2022 | Aug 3, 2022 | Nath Kabir | CEO | Neutral | 90.0 | +50,000 | 100.00% | ✗ | - |
| Aug 3, 2022 | Nath Kabir | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jun 16, 2022 | Jun 17, 2022 | McQuade Robert | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 16, 2022 | Jun 17, 2022 | Lonngren Thomas | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 16, 2022 | Jun 17, 2022 | McGoldrick Linda | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 16, 2022 | Jun 17, 2022 | Riley Wayne Joseph | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 16, 2022 | Jun 17, 2022 | Norton David Y | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |